Blueprint TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update Company solidifies balance sheet with approximately $89M in gross proceeds through the combination of $57.5

TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2016

Financial Results and Business Update

Company solidifies balance sheet with approximately $89M in gross

proceeds through the combination of $57.5M public offering and $31M

from at-the-market (ATM) sales

facility completed prior to the offering

Investor conference call to be held today, Friday March 10, 2017 at

York, NY, (March 10, 2017)

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its

financial results for the fourth quarter and year ended December

31, 2016 and provided recent company developments along with a

business outlook for 2017.

Company announced that through the combination of an underwritten

public offering, and proceeds raised through the utilization of an

ATM program, the Company raised combined gross proceeds of

approximately $89M before deducting underwriting discounts and

commissions and other estimated offering expenses. The underwritten

offering consisted of 5,128,206 shares of its common stock (plus a

30-day option to purchase up to an additional 769,230 shares of

common stock, which has been exercised) at a price of $9.75 per

share, with expected gross proceeds to TG Therapeutics of $57.5

million, less underwriting discounts and commissions. The offering

is expected to close on or about March 14, 2017, subject to the

satisfaction of customary closing conditions. Prior to the public

offering, the Company also issued approximately 3,000,000 shares

through the ATM program for gross proceeds of approximately $31

million at an average price of $10.27, these shares were issued on

S. Weiss, the Company's Executive Chairman and Chief Executive

Officer, stated, "2016 was a very productive year for the Company,

laying the foundation for pivotal data read-outs in 2017 and 2018.

The first of which were reported earlier this week, with the

announcement of the positive topline results from our Phase 3

GENUINE clinical trial. For the remainder of 2017, we look forward

to the full data presentation from the GENUINE trial in the summer

and then in the second half to a meeting with the FDA to discuss a

filing for accelerated approval. All along we will continue to

remain highly focused on enrolling into our proprietary UNITY

programs, which are proceeding nicely and on schedule. Mr.

Weiss continued, This week we also had the opportunity to

solidify our cash reserves with the recently conducted offerings,

which should provide us with sufficient capital to advance our key

programs and get us closer to our goal of bringing our novel

treatment options to patients with B-cell

enrollment in our Phase 3 GENUINE clinical trial, which resulted in

positive topline data

UNITY-CLL Phase 3 and UNITY-DLBCL Phase 2b trials for the

combination of TG-1101 + TGR-1202

positive outcome of our UNITY-CLL Phase 3 DSMB safety review

meeting, pursuant to which the study was recommended to continue

enrolling both front-line and previously treated patients with no

changes recommended to the study

clinical trial in Multiple Sclerosis (MS) for TG-1101

issuance of composition of matter patents for both TG-1101 and

TGR-1202 providing protection through 2029 and 2033, respectively,

both exclusive of available patent term extensions

publications in prestigious journals, the first in BLOOD describing a novel mechanism of

TGR-1202 with potential in cMYC driven malignancies, and the second

in the British Journal of Haematology with data from our Phase 2

clinical trial of TG-1101 plus ibrutinib in patients with Chronic

Lymphocytic Leukemia (CLL)

the ASH annual meeting including 3 oral presentations and 3 poster

presentations, with a focus on combination therapy

Key Objectives for 2017

clinical data including the full Phase 3 GENUINE data at a major

medical meeting in the first half of 2017

data from the Phase 2 Multiple Sclerosis (MS) trial

interim analysis in the UNITY-CLL Phase 3 trial

interim analysis in the UNITY-DLBCL trial

to review the GENUINE Phase 3 data and discuss suitability for

filing for accelerated approval

new and updated data from ongoing trials at various scientific

meetings throughout the year, including the ASH annual meeting in

Financial Results for the Fourth Quarter and Full Year

Cash, cash equivalents, investment

securities, and interest receivable were $45.0 million as of

December 31, 2016. During the

first quarter of 2017 the Company raised approximately $84 million of net proceeds from the

underwritten public offering of the Company's common stock

and the utilization of the Company's at-the-market ("ATM")

Research and development (R&D)

expenses were $22.3 million and $69.2 million for the three and

twelve months ended December 31, 2016, respectively, compared to

$15.3 million and $47.7 million for the three and twelve months

ended December 31, 2015, respectively. Included in research and

development expenses for the three and twelve months ended December

31, 2016, are $9.1 million and $27.0 million, respectively, of

manufacturing and CMC expenses for Phase 3 clinical trials and

potential commercialization. The increase in R&D expenses for

both the three and twelve months ended December 31, 2016, is

primarily due to the ongoing clinical development programs and

related manufacturing costs for TG-1101 and

General and administrative (G&A)

expenses were $1.8 million and $9.9 million for the three and

twelve months ended December 31, 2016, respectively, as compared to

$2.4 million and $15.6 million for the three and twelve months

ended December 31, 2015, respectively. The period-over-period

decrease in G&A expenses from three and twelve months ended

December 31, 2015 relates primarily to non-cash compensation

expenses related to equity incentive expense recognized during

Net Loss: Net loss was $23.7 million and $78.3 million for